MedPath
Found 33 clinical trials|View Analysis
Sort by:

Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST

Phase 1
Not yet recruiting
Conditions
Malignant Peripheral Nerve Sheath Tumor (MPNST)
Neurofibromatosis 1 (NF1)
Atypical Neurofibroma
Interventions
Drug: APG-115
Drug: Selumetinib
First Posted Date
2024-12-16
Last Posted Date
2024-12-16
Lead Sponsor
AeRang Kim
Target Recruit Count
45
Registration Number
NCT06735820
Locations
🇺🇸

Children's National Hospital, Washington, District of Columbia, United States

A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]

Early Phase 1
Not yet recruiting
Conditions
Primary Malignant Peripheral Nerve Sheath Tumors
Interventions
First Posted Date
2024-11-18
Last Posted Date
2024-11-18
Lead Sponsor
University of Minnesota
Target Recruit Count
8
Registration Number
NCT06693284

Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Extremity Soft Tissue Sarcoma

Not Applicable
Not yet recruiting
Conditions
AJCC Grade 3 Sarcoma
Extraskeletal Ewing Sarcoma
Fibrosarcoma
Soft Tissue Sarcoma
Soft Tissue Sarcoma of the Trunk and Extremities
Alveolar Soft Part Sarcoma
Clear Cell Sarcoma of Soft Tissue
Leiomyosarcoma
Malignant Peripheral Nerve Sheath Tumor
Sarcoma
Interventions
Procedure: Biopsy
Procedure: Chest Computed Tomography
Other: Quality-of-Life Assessment
Procedure: Chest Radiography
Other: Questionnaire Administration
First Posted Date
2024-07-30
Last Posted Date
2024-07-30
Lead Sponsor
ECOG-ACRIN Cancer Research Group
Target Recruit Count
1582
Registration Number
NCT06526897

Neurofibromatosis Type 1 Tumor Early Detection Study

Recruiting
Conditions
Neurofibromatosis Type 1
Neurofibromatosis 1
Plexiform Neurofibroma
Plexiform Neurofibromas
Atypical Neurofibroma
Malignant Peripheral Nerve Sheath Tumor
Malignant Peripheral Nerve Sheath Tumors
First Posted Date
2024-07-23
Last Posted Date
2024-08-26
Lead Sponsor
David Miller
Target Recruit Count
1000
Registration Number
NCT06515860
Locations
🇺🇸

Boston Children's Hospital, Boston, Massachusetts, United States

Multi-parametric Biomarker Development to Predict Malignant Conversion in Patients With Neurofibromatosis Type 1

Active, not recruiting
Conditions
Malignant Peripheral Nerve Sheath Tumor (MPNST) of Soft Tissue (Diagnosis)
Neurofibromatosis 1
Atypical Neurofibroma
First Posted Date
2023-01-10
Last Posted Date
2025-01-06
Lead Sponsor
Johns Hopkins University
Target Recruit Count
80
Registration Number
NCT05677594
Locations
🇺🇸

Johns Hopkins University, Baltimore, Maryland, United States

SPEARHEAD-3 Pediatric Study

Phase 1
Recruiting
Conditions
Synovial Sarcoma
Malignant Peripheral Nerve Sheath Tumor (MPNST)
Neuroblastoma
Osteosarcoma
Interventions
Genetic: Afamitresgene autoleucel
First Posted Date
2022-12-08
Last Posted Date
2024-04-24
Lead Sponsor
Adaptimmune
Target Recruit Count
20
Registration Number
NCT05642455
Locations
🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Stanford University, Palo Alto, California, United States

🇺🇸

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

and more 8 locations

A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients

Phase 1
Active, not recruiting
Conditions
Soft Tissue Sarcoma
Malignant Peripheral Nerve Sheath Tumor (MPNST)
Leiomyosarcoma
Endometrial Stromal Sarcoma
Interventions
First Posted Date
2021-03-23
Last Posted Date
2024-03-18
Lead Sponsor
University Health Network, Toronto
Target Recruit Count
56
Registration Number
NCT04811196
Locations
🇨🇦

Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Incidence of Malignant Peripheral Nerve Sheath Tumor (MPNST) Development in Participants With Neurofibromatosis Type 1 (NF1) Receiving and Not Receiving Medical Therapies Directed at Plexiform Neurofibromas (PN)

Completed
Conditions
Neurofibromatosis 1
Peripheral Nerve Neoplasms, Malignant
First Posted Date
2021-03-01
Last Posted Date
2024-06-26
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
296
Registration Number
NCT04774289
Locations
🇺🇸

National Cancer Institute (NCI), Bethesda, Maryland, United States

Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults

Phase 2
Terminated
Conditions
Refractory Malignant Peripheral Nerve Sheath Tumor
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Recurrent Neuroblastoma
Recurrent Rhabdomyosarcoma
Refractory Malignant Solid Neoplasm
Desmoplastic Small Round Cell Tumor
Recurrent Malignant Peripheral Nerve Sheath Tumor
Refractory Desmoplastic Small Round Cell Tumor
Recurrent Desmoplastic Small Round Cell Tumor
Recurrent Malignant Solid Neoplasm
Interventions
First Posted Date
2020-08-28
Last Posted Date
2024-10-26
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
40
Registration Number
NCT04530487
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor

Phase 1
Recruiting
Conditions
Nerve Sheath Tumors
Interventions
First Posted Date
2020-07-10
Last Posted Date
2024-06-21
Lead Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Target Recruit Count
18
Registration Number
NCT04465643
Locations
🇺🇸

Johns Hopkins Medical Institution, Baltimore, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath